Etsuko Miyagi

ORCID: 0000-0002-5492-0844 · 20 papers in corpus
observational 2025
The journal of obstetrics and gynaecology research ·doi:10.1111/jog.16241

AIM: Tissue factor pathway inhibitor 2 (TFPI2) is a preoperative biomarker that was developed to discriminate ovarian benign tumors from cancer and is covered by health insurance in Japan. The purpose of this study was to evaluate how the T…

other 2024
BMC cancer ·doi:10.1186/s12885-024-12827-0

BACKGROUND: Endometrial cancer is the most common gynecological malignancy; however, there is no useful blood diagnostic biomarker. This study aimed to determine the utility of tissue factor pathway inhibitor 2 (TFPI2), a biomarker of ovari…

case-report 2023
·doi:10.5180/jsgoe.39.1_41

We report a case in which umbilical endometriosis was resected and the umbilicus was used as an insufflation port for laparoscopic right adnexectomy before umbilicoplasty.

other 2022
Asian journal of andrology ·doi:10.4103/aja202152
case-report 2022
·doi:10.5180/jsgoe.38.2_235

A 40-year-old G0P0 presented with uterine leiomyomas and underwent total laparoscopic hysterectomy and bilateral salpingectomy for management of worsening hypermenorrhea. Intraperitoneal findings included an endometriotic lesion (approximat…

observational 2021
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.14862

AIM: During pregnancy, the ovarian endometrioma generally decreases in size and occasionally ruptures. We evaluated (1) whether and how ovarian-endometrioma size changes from the first trimester to the postdelivery period, and (2) the type …

observational 2021
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.14612

AIM: Dienogest (DNG) is highly effective for relieving pain caused by endometriosis and adenomyosis. However, women with severe uterine swelling due to adenomyosis who take DNG usually experience metrorrhagia. This study aimed to examine th…

diagnostic-accuracy 2021
International journal of clinical oncology ·doi:10.1007/s10147-021-01914-y

BACKGROUND: Tissue factor pathway inhibitor 2 (TFPI2) is a novel serum biomarker that discriminates ovarian clear cell carcinoma (CCC) from borderline ovarian tumors (BOTs) and non-clear cell epithelial ovarian cancers (EOCs). Here, we exam…

case-report 2020
Clinical case reports ·doi:10.1002/ccr3.3524

Because the anterior lower uterine segment is stretched, the incarcerated gravid uterus case with a history of cesarean section is a good candidate for manual reduction.

case-report 2018
Clinical case reports ·doi:10.1002/ccr3.1554

As labor may mask a symptom of the rupture of ovarian cyst and delivery is a risk factor of its rupture, the possibility of rupture of ovarian cyst should always be considered during delivery.

case-report 2018
Case Reports in Obstetrics and Gynecology ·doi:10.1155/2018/6968382

Asherman's syndrome is defined as partial or complete obstruction of the uterine cavity primarily caused by intrauterine procedures and infections. Hysteroscopic adhesiolysis is commonly used to treat Asherman's syndrome. Although the frequ…

diagnostic-accuracy 2016
PloS one ·doi:10.1371/journal.pone.0165609

BACKGROUND: There is currently no reliable serum biomarker for ovarian clear cell carcinoma (CCC), a highly lethal histological subtype of epithelial ovarian cancer (EOC). Previously, using a proteome-based approach, we identified tissue fa…

diagnostic-accuracy 2016
International journal of clinical oncology ·doi:10.1007/s10147-016-1035-4

BACKGROUND: We previously developed a new plasma amino acid profile-based index (API) to detect ovarian, cervical, and endometrial cancers. Here, we compared API to serum cancer antigen 125 (CA125) for distinguishing epithelial ovarian mali…

case-report 2016
Diagnostic pathology ·doi:10.1186/s13000-016-0585-0

BACKGROUND: Uterine serous endometrial intraepithelial carcinoma (SEIC) is an immediate precursor of invasive carcinoma. The majority of stage IA SEICs are curable, but those with latent peritoneal metastasis and/or capillary lymphatics inv…

case-report 2014
Pathology international ·doi:10.1111/pin.12151

Endometrial stromal tumors (ESTs) are composed of cells resembling endometrial stroma, and are divided into benign and malignant types based on morphology. Endometrial stromal nodule (ESN) is a benign localized tumor, and endometrial stroma…

case-report 2013
Gynecologic oncology case reports ·doi:10.1016/j.gynor.2013.02.005

► Synchronous mucinous metaplasia and neoplasia of the female genital tract (SMMN-FGT) is a rare mucinous lesion. ► This is the first case of SMMN-FGT with DNA sequencing of STK11 and KRAS, but no mutation was identified.

lab-animal 2013
PloS one ·doi:10.1371/journal.pone.0080359

Ovarian clear cell adenocarcinoma (CCC) is the second most common subtype of ovarian cancer after high-grade serous adenocarcinomas. CCC tends to develop resistance to the standard platinum-based chemotherapy, and has a poor prognosis when …

other 2013
Journal of proteome research ·doi:10.1021/pr400282j

Of all of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma (CCA) has the worst clinical prognosis. Furthermore, the conventional EOC biomarker CA125 is more often negative in CCA than in other subtypes of EOC. This study soug…

other 2012
Cancer biology & therapy ·doi:10.4161/cbt.20084

Inflammatory cells play important roles in progression of solid neoplasms including ovarian cancers. Tumor-associated macrophages (TAMs) contribute to angiogenesis and immune suppression by modulating microenvironment. Ovarian cancer develo…

other 2011
Gynecologic Oncology ·doi:10.1016/j.ygyno.2011.05.034

OBJECTIVES: Carcinogenesis of the ovary is often associated with endometriosis. We previously demonstrated that antitumor chemokine receptor CXCR3 was upregulated both in endometriosis and ovarian cancers. Currently, little is known about t…